デフォルト表紙
市場調査レポート
商品コード
1455603

PCRベース感染症の世界市場 - 産業動向、予測(~2031年)

Global PCR-based Infectious Diseases Market - Industry Trends and Forecast to 2031

出版日: | 発行: Data Bridge Market Research | ページ情報: 英文 476 Pages | 納期: お問合せ

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=159.16円
PCRベース感染症の世界市場 - 産業動向、予測(~2031年)
出版日: 2024年02月01日
発行: Data Bridge Market Research
ページ情報: 英文 476 Pages
納期: お問合せ
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のPCRベース感染症の市場規模は、2023年に47億3,757万米ドル、2031年に77億2,089万5,130米ドルに達し、2024年~2031年の予測期間にCAGRで6.6%の成長が見込まれます。

当レポートでは、世界のPCRベース感染症市場について調査分析し、産業動向と予測、促進要因と抑制要因、企業情勢などの情報を提供しています。

目次

第1章 イントロダクション

第2章 市場セグメンテーション

第3章 エグゼクティブサマリー

第4章 重要考察

  • PESTEL分析
  • ポーターのファイブフォース分析

第5章 市場の概要

  • 促進要因
    • PCRベースの研究活動の増加
    • 感染症の増加
    • 疾患の診断を推進する政府の取り組みとキャンペーン
  • 抑制要因
    • PCR検査サービスの高いコスト
    • 熟練した検査技師の不足
  • 機会
    • 感染症の早期発見とモニタリングに向けた疾患調査
    • PCR技術における革新の高まり
    • ターゲットを絞った効果的な介入に向けた個別化PCRベース戦略
  • 課題
    • データセキュリティとプライバシーに関する懸念
    • 複雑性と技術的専門知識

第6章 世界のPCRベース感染症市場:検査タイプ別

  • 概要
  • 結核PCR検査
  • 肝炎PCR検査
    • C型肝炎PCR検査
    • B型肝炎PCR検査
  • ヒト免疫不全ウイルス(HIV)PCR検査
  • インフルエンザPCR検査
  • ヒトパピローマウイルス(HPV)PCR検査
  • クラミジアトラコマティス性器感染症PCR検査
  • 淋病PCR検査
  • サルモネラ症PCR検査
  • ロタウイルスPCR検査
  • ボルデテラPCR検査
  • H.ピロリPCR検査
  • SARS(COVID-19)感染症
  • ノロウイルスPCR検査
  • C.ディフィシル(クロストリジウムディフィシル)PCR検査
  • カルバペネム耐性腸内細菌(CRE)PCR検査
  • 腸球菌PCR検査
  • マイコプラズマジェニタリウム(MG)PCR検査
  • メチシリン耐性黄色ブドウ球菌(MRSA)PCR検査
  • その他のPCR検査

第7章 世界のPCRベース感染症市場:感染症別

  • 概要
  • ウイルス感染症
    • SARS(COVID-19)感染症
    • ロタウイルス感染症
    • ノロウイルス感染症
    • その他
  • 呼吸器感染症
    • インフルエンザ
    • 結核
    • ボルデテラ
  • 性感染症
    • クラミジアトラコマティス性器感染症
    • 淋病
    • 肝炎
    • ヒト免疫不全ウイルス(HIV)
    • ヒトパピローマウイルス(HPV)
    • マイコプラズマジェニタリウム(MG)
    • その他
  • 院内感染
    • C.ディフィシル(クロストリジウムディフィシル)
    • カルバペネム耐性腸内細菌(CRE)
    • メチシリン耐性黄色ブドウ球菌(MRSA)
    • その他
  • その他の感染症
    • サルモネラ症
    • ピロリ菌
    • 腸球菌感染症
    • その他

第8章 世界のPCRベース感染症市場:病原体別

  • 概要
  • ウイルス
  • 細菌
  • 真菌
  • 原虫
  • その他

第9章 世界のPCRベース感染症市場:技術別

  • 概要
  • RT PCR検査
  • マルチプレックスPCR
  • その他

第10章 世界のPCRベース感染症市場:患者タイプ別

  • 概要
  • 高齢者
  • 小児
  • 成人

第11章 世界のPCRベース感染症市場:検査別

  • 概要
  • 実験室ベース検査
  • ポイントオブケア検査

第12章 世界のPCRベース感染症市場:エンドユーザー別

  • 概要
  • 診断センター
  • 病院
  • 診療所
  • コミュニティヘルスセンター
  • 学術研究機関
  • 在宅医療
  • その他

第13章 世界のPCRベース感染症市場:地域別

  • 概要
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • ロシア
    • スペイン
    • トルコ
    • オランダ
    • スイス
    • ベルギー
    • ハンガリー
    • その他の欧州
  • アジア太平洋
    • 中国
    • オーストラリア
    • 日本
    • インド
    • 韓国
    • シンガポール
    • マレーシアの語
    • タイ
    • インドネシア
    • フィリピン
    • その他のアジア太平洋
  • 南米
    • ブラジル
    • アルゼンチン
    • その他の南米
  • 中東・アフリカ
    • 南アフリカ
    • アラブ首長国連邦
    • サウジアラビア
    • エジプト
    • イスラエル
    • その他の中東・アフリカ

第14章 世界のPCRベース感染症市場:企業情勢

  • 企業シェア分析:世界

第15章 SWOT分析

第16章 企業プロファイル

  • MICROGEN DIAGNOSTICS
  • MAX LAB
  • DNA LABS INDIA
  • GANESH DIAGNOSTIC & IMAGING CENTRE PVT. LTD.
  • LALPATHLABS
  • AZOVA
  • CLAREWELL CLINICS
  • DRSAFEHANDS
  • ONE LIFE HOME HEALTH CARE CENTER
  • PATHLAB
  • THE WASHINGTON TRAVEL CLINIC

第17章 アンケート

第18章 関連レポート

図表

LIST OF TABLES

  • TABLE 1 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 85
  • TABLE 2 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 86
  • TABLE 3 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 87
  • TABLE 4 GLOBAL TUBERCULOSIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 88
  • TABLE 5 GLOBAL HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 88
  • TABLE 6 GLOBAL HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 89
  • TABLE 7 GLOBAL HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 89
  • TABLE 8 GLOBAL HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 89
  • TABLE 9 GLOBAL HUMAN IMMUNODEFICIENCY VIRUS (HIV) PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 90
  • TABLE 10 GLOBAL INFLUENZA PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 90
  • TABLE 11 GLOBAL HUMAN PAPILLOMAVIRUS (HPV) PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 91
  • TABLE 12 GLOBAL CHLAMYDIA TRACHOMATIS GENITAL PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 91
  • TABLE 13 GLOBAL GONORRHEA PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 92
  • TABLE 14 GLOBAL SALMONELLOSIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 92
  • TABLE 15 GLOBAL ROTAVIRUS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 93
  • TABLE 16 GLOBAL BORDETELLA PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 93
  • TABLE 17 GLOBAL H. PYLORI PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 94
  • TABLE 18 GLOBAL SARS (COVID-19) PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 94
  • TABLE 19 GLOBAL NOROVIRUS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 95
  • TABLE 20 GLOBAL C.DIFFICILE (CLOSTRIDIUM DIFFICILE) PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 95
  • TABLE 21 GLOBAL CARBAPENEM-RESISTANT ENTEROBACTERIACEAE (CRE) PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 96
  • TABLE 22 GLOBAL ENTEROCOCCUS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 96
  • TABLE 23 GLOBAL MYCOPLASMA GENITALIUM (MG) PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 97
  • TABLE 24 GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 97
  • TABLE 25 GLOBAL OTHERS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 98
  • TABLE 26 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 102
  • TABLE 27 GLOBAL VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 103
  • TABLE 28 GLOBAL VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 103
  • TABLE 29 GLOBAL RESPIRATORY TRACT INFECTION IN PCR-BASED INFFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 104
  • TABLE 30 GLOBAL RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 104
  • TABLE 31 GLOBAL SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 105
  • TABLE 32 GLOBAL SEXUALLY TRANSMITTED INFECTION IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 105
  • TABLE 33 GLOBAL HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 107
  • TABLE 34 GLOBAL HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 107
  • TABLE 35 GLOBAL OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 108
  • TABLE 36 GLOBAL OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 108
  • TABLE 37 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 113
  • TABLE 38 GLOBAL VIRAL IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 114
  • TABLE 39 GLOBAL BACTERIAL IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 114
  • TABLE 40 GLOBAL FUNGAL IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 115
  • TABLE 41 GLOBAL PROTOZOA IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 115
  • TABLE 42 GLOBAL OTHERS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 116
  • TABLE 43 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 120
  • TABLE 44 GLOBAL RT PCR IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 121
  • TABLE 45 GLOBAL MULTIPLEX PCR IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 121
  • TABLE 46 GLOBAL OTHERS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 122
  • TABLE 47 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 126
  • TABLE 48 GLOBAL GERIATRIC IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 127
  • TABLE 49 GLOBAL PEDIATRIC IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 127
  • TABLE 50 GLOBAL ADULTS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 128
  • TABLE 51 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 132
  • TABLE 52 GLOBAL LABORATORY BASED TESTING IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 133
  • TABLE 53 GLOBAL POINT OF CARE TESTING IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 133
  • TABLE 54 GLOBAL PCR-BASED INFECTIOUS DISEASES MARKET, BY END USER, 2022-2031 (USD THOUSAND) 137
  • TABLE 55 GLOBAL DIAGNOSTIC CENTERS IN PCR-BASED INFECTIOUS DISEASES MARKET, BY REGION, 2022-2031 (USD THOUSAND) 138
  • TABLE 56 GLOBAL HOSPITAL IN PCR-BASED INFECTIOUS DISEASES MARKET, BY REGION, 2022-2031 (USD THOUSAND) 138
  • TABLE 57 GLOBAL CLINICS IN PCR-BASED INFECTIOUS DISEASES MARKET, BY REGION, 2022-2031 (USD THOUSAND) 139
  • TABLE 58 GLOBAL COMMUNITY HEALTH CENTERS IN PCR-BASED INFECTIOUS DISEASES MARKET, BY REGION, 2022-2031 (USD THOUSAND) 139
  • TABLE 59 GLOBAL ACADEMIC AND RESEARCH INSTITUTES IN PCR-BASED INFECTIOUS DISEASES MARKET, BY REGION, 2022-2031 (USD THOUSAND) 140
  • TABLE 60 GLOBAL HOME HEALTHCARE IN PCR-BASED INFECTIOUS DISEASES MARKET, BY REGION, 2022-2031 (USD THOUSAND) 140
  • TABLE 61 GLOBAL OTHERS IN PCR-BASED INFECTIOUS DISEASES MARKET, BY REGION, 2022-2031 (USD THOUSAND) 141
  • TABLE 62 GLOBAL PCR-BASED INFECTIOUS DISEASES MARKET, BY REGION, 2022-2031 (USD THOUSAND) 146
  • TABLE 63 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND) 147
  • TABLE 64 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 148
  • TABLE 65 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 149
  • TABLE 66 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 150
  • TABLE 67 NORTH AMERICA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 151
  • TABLE 68 NORTH AMERICA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 151
  • TABLE 69 NORTH AMERICA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 151
  • TABLE 70 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 151
  • TABLE 71 NORTH AMERICA VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 152
  • TABLE 72 NORTH AMERICA RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 152
  • TABLE 73 NORTH AMERICA SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 153
  • TABLE 74 NORTH AMERICA HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 153
  • TABLE 75 NORTH AMERICA OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 154
  • TABLE 76 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 154
  • TABLE 77 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 154
  • TABLE 78 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 155
  • TABLE 79 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 155
  • TABLE 80 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 155
  • TABLE 81 U.S. PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 156
  • TABLE 82 U.S. PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 157
  • TABLE 83 U.S. PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 158
  • TABLE 84 U.S. HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 159
  • TABLE 85 U.S. HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 159
  • TABLE 86 U.S. HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 159
  • TABLE 87 U.S. PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 159
  • TABLE 88 U.S. VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 160
  • TABLE 89 U.S. RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 160
  • TABLE 90 U.S. SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 161
  • TABLE 91 U.S. HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 161
  • TABLE 92 U.S. OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 162
  • TABLE 93 U.S. PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 162
  • TABLE 94 U.S. PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 162
  • TABLE 95 U.S. PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 163
  • TABLE 96 U.S. PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 163
  • TABLE 97 U.S. PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 163
  • TABLE 98 CANADA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 164
  • TABLE 99 CANADA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 165
  • TABLE 100 CANADA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 166
  • TABLE 101 CANADA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 167
  • TABLE 102 CANADA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 167
  • TABLE 103 CANADA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 167
  • TABLE 104 CANADA PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 167
  • TABLE 105 CANADA VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 168
  • TABLE 106 CANADA RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 168
  • TABLE 107 CANADA SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 169
  • TABLE 108 CANADA HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 169
  • TABLE 109 CANADA OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 170
  • TABLE 110 CANADA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 170
  • TABLE 111 CANADA PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 170
  • TABLE 112 CANADA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 171
  • TABLE 113 CANADA PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 171
  • TABLE 114 CANADA PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 171
  • TABLE 115 MEXICO PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 172
  • TABLE 116 MEXICO PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 173
  • TABLE 117 MEXICO PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 174
  • TABLE 118 MEXICO HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 175
  • TABLE 119 MEXICO HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 175
  • TABLE 120 MEXICO HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 175
  • TABLE 121 MEXICO PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 175
  • TABLE 122 MEXICO VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 176
  • TABLE 123 MEXICO RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 176
  • TABLE 124 MEXICO SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 177
  • TABLE 125 MEXICO HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 177
  • TABLE 126 MEXICO OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 178
  • TABLE 127 MEXICO PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 178
  • TABLE 128 MEXICO PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 178
  • TABLE 129 MEXICO PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 179
  • TABLE 130 MEXICO PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 179
  • TABLE 131 MEXICO PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 179
  • TABLE 132 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND) 180
  • TABLE 133 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 181
  • TABLE 134 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 182
  • TABLE 135 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 183
  • TABLE 136 EUROPE HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 184
  • TABLE 137 EUROPE HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 184
  • TABLE 138 EUROPE HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 184
  • TABLE 139 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 184
  • TABLE 140 EUROPE VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 185
  • TABLE 141 EUROPE RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 185
  • TABLE 142 EUROPE SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 186
  • TABLE 143 EUROPE HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 186
  • TABLE 144 EUROPE OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 187
  • TABLE 145 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 187
  • TABLE 146 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 187
  • TABLE 147 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 188
  • TABLE 148 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 188
  • TABLE 149 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 188
  • TABLE 150 GERMANY PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 189
  • TABLE 151 GERMANY PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 190
  • TABLE 152 GERMANY PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 191
  • TABLE 153 GERMANY HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 192
  • TABLE 154 GERMANY HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 192
  • TABLE 155 GERMANY HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 192
  • TABLE 156 GERMANY PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 192
  • TABLE 157 GERMANY VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 193
  • TABLE 158 GERMANY RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 193
  • TABLE 159 GERMANY SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 194
  • TABLE 160 GERMANY HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 194
  • TABLE 161 GERMANY OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 195
  • TABLE 162 GERMANY PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 195
  • TABLE 163 GERMANY PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 195
  • TABLE 164 GERMANY PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 196
  • TABLE 165 GERMANY PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 196
  • TABLE 166 GERMANY PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 196
  • TABLE 167 FRANCE PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 197
  • TABLE 168 FRANCE PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 198
  • TABLE 169 FRANCE PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 199
  • TABLE 170 FRANCE HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 200
  • TABLE 171 FRANCE HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 200
  • TABLE 172 FRANCE HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 200
  • TABLE 173 FRANCE PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 200
  • TABLE 174 FRANCE VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 201
  • TABLE 175 FRANCE RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 201
  • TABLE 176 FRANCE SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 202
  • TABLE 177 FRANCE HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 202
  • TABLE 178 FRANCE OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 203
  • TABLE 179 FRANCE PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 203
  • TABLE 180 FRANCE PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 203
  • TABLE 181 FRANCE PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 204
  • TABLE 182 FRANCE PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 204
  • TABLE 183 FRANCE PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 204
  • TABLE 184 U.K. PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 205
  • TABLE 185 U.K. PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 206
  • TABLE 186 U.K. PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 207
  • TABLE 187 U.K. HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 208
  • TABLE 188 U.K. HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 208
  • TABLE 189 U.K. HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 208
  • TABLE 190 U.K. PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 208
  • TABLE 191 U.K. VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 209
  • TABLE 192 U.K. RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 209
  • TABLE 193 U.K. SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 210
  • TABLE 194 U.K. HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 210
  • TABLE 195 U.K. OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 211
  • TABLE 196 U.K. PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 211
  • TABLE 197 U.K. PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 211
  • TABLE 198 U.K. PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 212
  • TABLE 199 U.K. PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 212
  • TABLE 200 U.K. PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 212
  • TABLE 201 ITALY PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 213
  • TABLE 202 ITALY PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 214
  • TABLE 203 ITALY PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 215
  • TABLE 204 ITALY HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 216
  • TABLE 205 ITALY HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 216
  • TABLE 206 ITALY HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 216
  • TABLE 207 ITALY PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 216
  • TABLE 208 ITALY VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 217
  • TABLE 209 ITALY RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 217
  • TABLE 210 ITALY SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 218
  • TABLE 211 ITALY HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 218
  • TABLE 212 ITALY OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 219
  • TABLE 213 ITALY PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 219
  • TABLE 214 ITALY PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 219
  • TABLE 215 ITALY PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 220
  • TABLE 216 ITALY PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 220
  • TABLE 217 ITALY PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 220
  • TABLE 218 RUSSIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 221
  • TABLE 219 RUSSIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 222
  • TABLE 220 RUSSIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 223
  • TABLE 221 RUSSIA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 224
  • TABLE 222 RUSSIA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 224
  • TABLE 223 RUSSIA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 224
  • TABLE 224 RUSSIA PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 224
  • TABLE 225 RUSSIA VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 225
  • TABLE 226 RUSSIA RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 225
  • TABLE 227 RUSSIA SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 226
  • TABLE 228 RUSSIA HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 226
  • TABLE 229 RUSSIA OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 227
  • TABLE 230 RUSSIA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 227
  • TABLE 231 RUSSIA PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 227
  • TABLE 232 RUSSIA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 228
  • TABLE 233 RUSSIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 228
  • TABLE 234 RUSSIA PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 228
  • TABLE 235 SPAIN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 229
  • TABLE 236 SPAIN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 230
  • TABLE 237 SPAIN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 231
  • TABLE 238 SPAIN HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 232
  • TABLE 239 SPAIN HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 232
  • TABLE 240 SPAIN HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 232
  • TABLE 241 SPAIN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 232
  • TABLE 242 SPAIN VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 233
  • TABLE 243 SPAIN RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 233
  • TABLE 244 SPAIN SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 234
  • TABLE 245 SPAIN HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 234
  • TABLE 246 SPAIN OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 235
  • TABLE 247 SPAIN PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 235
  • TABLE 248 SPAIN PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 235
  • TABLE 249 SPAIN PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 236
  • TABLE 250 SPAIN PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 236
  • TABLE 251 SPAIN PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 236
  • TABLE 252 TURKEY PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 237
  • TABLE 253 TURKEY PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 238
  • TABLE 254 TURKEY PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 239
  • TABLE 255 TURKEY HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 240
  • TABLE 256 TURKEY HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 240
  • TABLE 257 TURKEY HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 240
  • TABLE 258 TURKEY PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 240
  • TABLE 259 TURKEY VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 241
  • TABLE 260 TURKEY RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 241
  • TABLE 261 TURKEY SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 242
  • TABLE 262 TURKEY HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 242
  • TABLE 263 TURKEY OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 243
  • TABLE 264 TURKEY PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 243
  • TABLE 265 TURKEY PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 243
  • TABLE 266 TURKEY PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 244
  • TABLE 267 TURKEY PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 244
  • TABLE 268 TURKEY PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 244
  • TABLE 269 NETHERLANDS PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 245
  • TABLE 270 NETHERLANDS PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 246
  • TABLE 271 NETHERLANDS PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 247
  • TABLE 272 NETHERLANDS HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 248
  • TABLE 273 NETHERLANDS HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 248
  • TABLE 274 NETHERLANDS HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 248
  • TABLE 275 NETHERLANDS PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 248
  • TABLE 276 NETHERLANDS VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 249
  • TABLE 277 NETHERLANDS RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 249
  • TABLE 278 NETHERLANDS SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 250
  • TABLE 279 NETHERLANDS HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 250
  • TABLE 280 NETHERLANDS OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 251
  • TABLE 281 NETHERLANDS PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 251
  • TABLE 282 NETHERLANDS PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 251
  • TABLE 283 NETHERLANDS PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 252
  • TABLE 284 NETHERLANDS PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 252
  • TABLE 285 NETHERLANDS PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 252
  • TABLE 286 SWITZERLAND PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 253
  • TABLE 287 SWITZERLAND PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 254
  • TABLE 288 SWITZERLAND PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 255
  • TABLE 289 SWITZERLAND HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 256
  • TABLE 290 SWITZERLAND HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 256
  • TABLE 291 SWITZERLAND HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 256
  • TABLE 292 SWITZERLAND PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 256
  • TABLE 293 SWITZERLAND VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 257
  • TABLE 294 SWITZERLAND RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 257
  • TABLE 295 SWITZERLAND SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 258
  • TABLE 296 SWITZERLAND HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 258
  • TABLE 297 SWITZERLAND OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 259
  • TABLE 298 SWITZERLAND PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 259
  • TABLE 299 SWITZERLAND PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 259
  • TABLE 300 SWITZERLAND PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 260
  • TABLE 301 SWITZERLAND PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 260
  • TABLE 302 SWITZERLAND PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 260
  • TABLE 303 BELGIUM PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 261
  • TABLE 304 BELGIUM PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 262
  • TABLE 305 BELGIUM PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 263
  • TABLE 306 BELGIUM HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 264
  • TABLE 307 BELGIUM HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 264
  • TABLE 308 BELGIUM HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 264
  • TABLE 309 BELGIUM PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 264
  • TABLE 310 BELGIUM VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 265
  • TABLE 311 BELGIUM RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 265
  • TABLE 312 BELGIUM SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 266
  • TABLE 313 BELGIUM HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 266
  • TABLE 314 BELGIUM OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 267
  • TABLE 315 BELGIUM PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 267
  • TABLE 316 BELGIUM PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 267
  • TABLE 317 BELGIUM PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 268
  • TABLE 318 BELGIUM PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 268
  • TABLE 319 BELGIUM PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 268
  • TABLE 320 HUNGARY PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 269
  • TABLE 321 HUNGARY PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 270
  • TABLE 322 HUNGARY PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 271
  • TABLE 323 HUNGARY HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 272
  • TABLE 324 HUNGARY HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 272
  • TABLE 325 HUNGARY HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 272
  • TABLE 326 HUNGARY PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 272
  • TABLE 327 HUNGARY VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 273
  • TABLE 328 HUNGARY RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 273
  • TABLE 329 HUNGARY SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 274
  • TABLE 330 HUNGARY HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 274
  • TABLE 331 HUNGARY OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 275
  • TABLE 332 HUNGARY PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 275
  • TABLE 333 HUNGARY PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 275
  • TABLE 334 HUNGARY PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 276
  • TABLE 335 HUNGARY PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 276
  • TABLE 336 HUNGARY PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 276
  • TABLE 337 REST OF EUROPE PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 277
  • TABLE 338 REST OF EUROPE PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 278
  • TABLE 339 REST OF EUROPE PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 279
  • TABLE 340 ASIA-PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND) 280
  • TABLE 341 ASIA-PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 281
  • TABLE 342 ASIA-PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 282
  • TABLE 343 ASIA-PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 283
  • TABLE 344 ASIA-PACIFIC HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 284
  • TABLE 345 ASIA-PACIFIC HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 284
  • TABLE 346 ASIA-PACIFIC HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 284
  • TABLE 347 ASIA-PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 284
  • TABLE 348 ASIA-PACIFIC VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 285
  • TABLE 349 ASIA-PACIFIC RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 285
  • TABLE 350 ASIA-PACIFIC SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 286
  • TABLE 351 ASIA-PACIFIC HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 286
  • TABLE 352 ASIA-PACIFIC OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 287
  • TABLE 353 ASIA-PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 287
  • TABLE 354 ASIA-PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 288
  • TABLE 355 ASIA-PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 288
  • TABLE 356 ASIA-PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 288
  • TABLE 357 ASIA-PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 289
  • TABLE 358 CHINA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 290
  • TABLE 359 CHINA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 291
  • TABLE 360 CHINA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 292
  • TABLE 361 CHINA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 293
  • TABLE 362 CHINA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 293
  • TABLE 363 CHINA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 293
  • TABLE 364 CHINA PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 293
  • TABLE 365 CHINA VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 294
  • TABLE 366 CHINA RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 294
  • TABLE 367 CHINA SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 295
  • TABLE 368 CHINA HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 295
  • TABLE 369 CHINA OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 296
  • TABLE 370 CHINA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 296
  • TABLE 371 CHINA PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 296
  • TABLE 372 CHINA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 297
  • TABLE 373 CHINA PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 297
  • TABLE 374 CHINA PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 297
  • TABLE 375 AUSTRALIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 298
  • TABLE 376 AUSTRALIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 299
  • TABLE 377 AUSTRALIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 300
  • TABLE 378 AUSTRALIA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 301
  • TABLE 379 AUSTRALIA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 301
  • TABLE 380 AUSTRALIA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 301
  • TABLE 381 AUSTRALIA PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 301
  • TABLE 382 AUSTRALIA VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 302
  • TABLE 383 AUSTRALIA RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 302
  • TABLE 384 AUSTRALIA SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 303
  • TABLE 385 AUSTRALIA HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 303
  • TABLE 386 AUSTRALIA OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 304
  • TABLE 387 AUSTRALIA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 304
  • TABLE 388 AUSTRALIA PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 304
  • TABLE 389 AUSTRALIA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 305
  • TABLE 390 AUSTRALIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 305
  • TABLE 391 AUSTRALIA PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 305
  • TABLE 392 JAPAN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 306
  • TABLE 393 JAPAN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 307
  • TABLE 394 JAPAN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 308
  • TABLE 395 JAPAN HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 309
  • TABLE 396 JAPAN HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 309
  • TABLE 397 JAPAN HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 309
  • TABLE 398 JAPAN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 309
  • TABLE 399 JAPAN VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 310
  • TABLE 400 JAPAN RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 310
  • TABLE 401 JAPAN SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 311
  • TABLE 402 JAPAN HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 311
  • TABLE 403 JAPAN OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 312
  • TABLE 404 JAPAN PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 312
  • TABLE 405 JAPAN PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 312
  • TABLE 406 JAPAN PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 313
  • TABLE 407 JAPAN PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 313
  • TABLE 408 JAPAN PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 313
  • TABLE 409 INDIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 314
  • TABLE 410 INDIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 315
  • TABLE 411 INDIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 316
  • TABLE 412 INDIA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 317
  • TABLE 413 INDIA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 317
  • TABLE 414 INDIA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 317
  • TABLE 415 INDIA PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 317
  • TABLE 416 INDIA VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 318
  • TABLE 417 INDIA RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 318
  • TABLE 418 INDIA SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 319
  • TABLE 419 INDIA HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 319
  • TABLE 420 INDIA OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 320
  • TABLE 421 INDIA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 320
  • TABLE 422 INDIA PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 320
  • TABLE 423 INDIA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 321
  • TABLE 424 INDIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 321
  • TABLE 425 INDIA PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 321
  • TABLE 426 SOUTH KOREA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 322
  • TABLE 427 SOUTH KOREA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 323
  • TABLE 428 SOUTH KOREA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 324
  • TABLE 429 SOUTH KOREA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 325
  • TABLE 430 SOUTH KOREA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 325
  • TABLE 431 SOUTH KOREA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 325
  • TABLE 432 SOUTH KOREA PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 325
  • TABLE 433 SOUTH KOREA VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 326
  • TABLE 434 SOUTH KOREA RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 326
  • TABLE 435 SOUTH KOREA SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 327
  • TABLE 436 SOUTH KOREA HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 327
  • TABLE 437 SOUTH KOREA OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 328
  • TABLE 438 SOUTH KOREA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 328
  • TABLE 439 SOUTH KOREA PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 328
  • TABLE 440 SOUTH KOREA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 329
  • TABLE 441 SOUTH KOREA PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 329
  • TABLE 442 SOUTH KOREA PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 329
  • TABLE 443 SINGAPORE PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 330
  • TABLE 444 SINGAPORE PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 331
  • TABLE 445 SINGAPORE PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 332
  • TABLE 446 SINGAPORE HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 333
  • TABLE 447 SINGAPORE HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 333
  • TABLE 448 SINGAPORE HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 333
  • TABLE 449 SINGAPORE PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 333
  • TABLE 450 SINGAPORE VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 334
  • TABLE 451 SINGAPORE RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 334
  • TABLE 452 SINGAPORE SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 335
  • TABLE 453 SINGAPORE HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 335
  • TABLE 454 SINGAPORE OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 336
  • TABLE 455 SINGAPORE PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 336
  • TABLE 456 SINGAPORE PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 336
  • TABLE 457 SINGAPORE PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 337
  • TABLE 458 SINGAPORE PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 337
  • TABLE 459 SINGAPORE PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 337
  • TABLE 460 MALAYSIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 338
  • TABLE 461 MALAYSIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 339
  • TABLE 462 MALAYSIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 340
  • TABLE 463 MALAYSIA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 341
  • TABLE 464 MALAYSIA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 341
  • TABLE 465 MALAYSIA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 341
  • TABLE 466 MALAYSIA PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 341
  • TABLE 467 MALAYSIA VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 342
  • TABLE 468 MALAYSIA RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 342
  • TABLE 469 MALAYSIA SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 343
  • TABLE 470 MALAYSIA HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 343
  • TABLE 471 MALAYSIA OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 344
  • TABLE 472 MALAYSIA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 344
  • TABLE 473 MALAYSIA PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 344
  • TABLE 474 MALAYSIA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 345
  • TABLE 475 MALAYSIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 345
  • TABLE 476 MALAYSIA PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 345
  • TABLE 477 THAILAND PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 346
  • TABLE 478 THAILAND PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 347
  • TABLE 479 THAILAND PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 348
  • TABLE 480 THAILAND HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 349
  • TABLE 481 THAILAND HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 349
  • TABLE 482 THAILAND HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 349
  • TABLE 483 THAILAND PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 349
  • TABLE 484 THAILAND VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 350
  • TABLE 485 THAILAND RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 350
  • TABLE 486 THAILAND SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 351
  • TABLE 487 THAILAND HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 351
  • TABLE 488 THAILAND OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 352
  • TABLE 489 THAILAND PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 352
  • TABLE 490 THAILAND PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 352
  • TABLE 491 THAILAND PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 353
  • TABLE 492 THAILAND PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 353
  • TABLE 493 THAILAND PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 353
  • TABLE 494 INDONESIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 354
  • TABLE 495 INDONESIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 355
  • TABLE 496 INDONESIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 356
  • TABLE 497 INDONESIA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 357
  • TABLE 498 INDONESIA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 357
  • TABLE 499 INDONESIA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 357
  • TABLE 500 INDONESIA PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 357
  • TABLE 501 INDONESIA VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 358
  • TABLE 502 INDONESIA RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 358
  • TABLE 503 INDONESIA SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 359
  • TABLE 504 INDONESIA HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 359
  • TABLE 505 INDONESIA OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 360
  • TABLE 506 INDONESIA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 360
  • TABLE 507 INDONESIA PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 360
  • TABLE 508 INDONESIA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 361
  • TABLE 509 INDONESIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 361
  • TABLE 510 INDONESIA PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 361
  • TABLE 511 PHILIPPINES PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 362
  • TABLE 512 PHILIPPINES PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 363
  • TABLE 513 PHILIPPINES PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 364
  • TABLE 514 PHILIPPINES HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 365
  • TABLE 515 PHILIPPINES HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 365
  • TABLE 516 PHILIPPINES HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 365
  • TABLE 517 PHILIPPINES PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 365
  • TABLE 518 PHILIPPINES VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 366
  • TABLE 519 PHILIPPINES RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 366
  • TABLE 520 PHILIPPINES SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 367
  • TABLE 521 PHILIPPINES HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 367
  • TABLE 522 PHILIPPINES OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 368
  • TABLE 523 PHILIPPINES PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 368
  • TABLE 524 PHILIPPINES PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 368
  • TABLE 525 PHILIPPINES PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 369
  • TABLE 526 PHILIPPINES PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 369
  • TABLE 527 PHILIPPINES PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 369
  • TABLE 528 REST OF ASIA-PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 370
  • TABLE 529 REST OF ASIA-PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 371
  • TABLE 530 REST OF ASIA-PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 372
  • TABLE 531 SOUTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND) 373
  • TABLE 532 SOUTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 374
  • TABLE 533 SOUTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 375
  • TABLE 534 SOUTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 376
  • TABLE 535 SOUTH AMERICA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 377
  • TABLE 536 SOUTH AMERICA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 377
  • TABLE 537 SOUTH AMERICA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 377
  • TABLE 538 SOUTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 377
  • TABLE 539 SOUTH AMERICA VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 378
  • TABLE 540 SOUTH AMERICA RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 378
  • TABLE 541 SOUTH AMERICA SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 379
  • TABLE 542 SOUTH AMERICA HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 379
  • TABLE 543 SOUTH AMERICA OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 380
  • TABLE 544 SOUTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 380
  • TABLE 545 SOUTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 380
  • TABLE 546 SOUTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 381
  • TABLE 547 SOUTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 381
  • TABLE 548 SOUTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 381
  • TABLE 549 BRAZIL PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 382
  • TABLE 550 BRAZIL PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 383
  • TABLE 551 BRAZIL PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 384
  • TABLE 552 BRAZIL HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 385
  • TABLE 553 BRAZIL HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 385
  • TABLE 554 BRAZIL HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 385
  • TABLE 555 BRAZIL PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 385
  • TABLE 556 BRAZIL VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 386
  • TABLE 557 BRAZIL RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 386
  • TABLE 558 BRAZIL SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 387
  • TABLE 559 BRAZIL HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 387
  • TABLE 560 BRAZIL OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 388
  • TABLE 561 BRAZIL PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 388
  • TABLE 562 BRAZIL PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 388
  • TABLE 563 BRAZIL PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 389
  • TABLE 564 BRAZIL PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 389
  • TABLE 565 BRAZIL PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 389
  • TABLE 566 ARGENTINA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 390
  • TABLE 567 ARGENTINA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 391
  • TABLE 568 ARGENTINA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 392
  • TABLE 569 ARGENTINA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 393
  • TABLE 570 ARGENTINA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 393
  • TABLE 571 ARGENTINA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 393
  • TABLE 572 ARGENTINA PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 393
  • TABLE 573 ARGENTINA VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 394
  • TABLE 574 ARGENTINA RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 394
  • TABLE 575 ARGENTINA SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 395
  • TABLE 576 ARGENTINA HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 395
  • TABLE 577 ARGENTINA OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 396
  • TABLE 578 ARGENTINA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 396
  • TABLE 579 ARGENTINA PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 396
  • TABLE 580 ARGENTINA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 397
  • TABLE 581 ARGENTINA PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 397
  • TABLE 582 ARGENTINA PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 397
  • TABLE 583 REST OF SOUTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 398
  • TABLE 584 REST OF SOUTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 399
  • TABLE 585 REST OF SOUTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 400
  • TABLE 586 MIDDLE EAST AND AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND) 401
  • TABLE 587 MIDDLE EAST AND AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 402
  • TABLE 588 MIDDLE EAST AND AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 403
  • TABLE 589 MIDDLE EAST AND AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 404
  • TABLE 590 MIDDLE EAST AND AFRICA HEPATITIS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 405
  • TABLE 591 MIDDLE EAST AND AFRICA HEPATITIS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 405
  • TABLE 592 MIDDLE EAST AND AFRICA HEPATITIS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 405
  • TABLE 593 MIDDLE EAST AND AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 405
  • TABLE 594 MIDDLE EAST AND AFRICA VIRAL INFECTION IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 406
  • TABLE 595 MIDDLE EAST AND AFRICA RESPIRATORY TRACT INFECTION IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 406
  • TABLE 596 MIDDLE EAST AND AFRICA SEXUALLY TRANSMITTED INFECTION IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 407
  • TABLE 597 MIDDLE EAST AND AFRICA HOSPITAL ACQUIRED INFECTIONS IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 407
  • TABLE 598 MIDDLE EAST AND AFRICA OTHER INFECTIONS IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 408
  • TABLE 599 MIDDLE EAST AND AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 408
  • TABLE 600 MIDDLE EAST AND AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 408
  • TABLE 601 MIDDLE EAST AND AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 409
  • TABLE 602 MIDDLE EAST AND AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 409
  • TABLE 603 MIDDLE EAST AND AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 409
  • TABLE 604 SOUTH AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 410
  • TABLE 605 SOUTH AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 411
  • TABLE 606 SOUTH AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 412
  • TABLE 607 SOUTH AFRICA HEPATITIS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 413
  • TABLE 608 SOUTH AFRICA HEPATITIS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 413
  • TABLE 609 SOUTH AFRICA HEPATITIS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 413
  • TABLE 610 SOUTH AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 413
  • TABLE 611 SOUTH AFRICA VIRAL INFECTION IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 414
  • TABLE 612 SOUTH AFRICA RESPIRATORY TRACT INFECTION IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 414
  • TABLE 613 SOUTH AFRICA SEXUALLY TRANSMITTED INFECTION IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 415
  • TABLE 614 SOUTH AFRICA HOSPITAL ACQUIRED INFECTIONS IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 415
  • TABLE 615 SOUTH AFRICA OTHER INFECTIONS IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 416
  • TABLE 616 SOUTH AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 416
  • TABLE 617 SOUTH AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 416
  • TABLE 618 SOUTH AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 417
  • TABLE 619 SOUTH AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 417
  • TABLE 620 SOUTH AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 417
  • TABLE 621 U.A.E. PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 418
  • TABLE 622 U.A.E. PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 419
  • TABLE 623 U.A.E. PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 420
  • TABLE 624 U.A.E. HEPATITIS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 421
  • TABLE 625 U.A.E. HEPATITIS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 421
  • TABLE 626 U.A.E. HEPATITIS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 421
  • TABLE 627 U.A.E. PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 421
  • TABLE 628 U.A.E. VIRAL INFECTION IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 422
  • TABLE 629 U.A.E. RESPIRATORY TRACT INFECTION IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 422
  • TABLE 630 U.A.E. SEXUALLY TRANSMITTED INFECTION IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 423
  • TABLE 631 U.A.E. HOSPITAL ACQUIRED INFECTIONS IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 423
  • TABLE 632 U.A.E. OTHER INFECTIONS IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 424
  • TABLE 633 U.A.E. PCR BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 424
  • TABLE 634 U.A.E. PCR BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 424
  • TABLE 635 U.A.E. PCR BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 425
  • TABLE 636 U.A.E. PCR BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 425
  • TABLE 637 U.A.E. PCR BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 425
  • TABLE 638 SAUDI ARABIA PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 426
  • TABLE 639 SAUDI ARABIA PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 427
  • TABLE 640 SAUDI ARABIA PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 428
  • TABLE 641 SAUDI ARABIA HEPATITIS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 429
  • TABLE 642 SAUDI ARABIA HEPATITIS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 429
  • TABLE 643 SAUDI ARABIA HEPATITIS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 429
  • TABLE 644 SAUDI ARABIA PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 429
  • TABLE 645 SAUDI ARABIA VIRAL INFECTION IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 430
  • TABLE 646 SAUDI ARABIA RESPIRATORY TRACT INFECTION IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 430
  • TABLE 647 SAUDI ARABIA SEXUALLY TRANSMITTED INFECTION IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 431
  • TABLE 648 SAUDI ARABIA HOSPITAL ACQUIRED INFECTIONS IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 431
  • TABLE 649 SAUDI ARABIA OTHER INFECTIONS IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 432
  • TABLE 650 SAUDI ARABIA PCR BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 432
  • TABLE 651 SAUDI ARABIA PCR BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 432
  • TABLE 652 SAUDI ARABIA PCR BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 433
  • TABLE 653 SAUDI ARABIA PCR BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 433
  • TABLE 654 SAUDI ARABIA PCR BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 433
  • TABLE 655 EGYPT PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 434
  • TABLE 656 EGYPT PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 435
  • TABLE 657 EGYPT PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 436
  • TABLE 658 EGYPT HEPATITIS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 437
  • TABLE 659 EGYPT HEPATITIS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 437
  • TABLE 660 EGYPT HEPATITIS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 437
  • TABLE 661 EGYPT PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 437
  • TABLE 662 EGYPT VIRAL INFECTION IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 438
  • TABLE 663 EGYPT RESPIRATORY TRACT INFECTION IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 438
  • TABLE 664 EGYPT SEXUALLY TRANSMITTED INFECTION IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 439
  • TABLE 665 EGYPT HOSPITAL ACQUIRED INFECTIONS IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 439
  • TABLE 666 EGYPT OTHER INFECTIONS IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 440
  • TABLE 667 EGYPT PCR BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 440
  • TABLE 668 EGYPT PCR BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 440
  • TABLE 669 EGYPT PCR BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 441
  • TABLE 670 EGYPT PCR BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 441
  • TABLE 671 EGYPT PCR BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 441
  • TABLE 672 ISRAEL PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 442
  • TABLE 673 ISRAEL PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 443
  • TABLE 674 ISRAEL PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 444
  • TABLE 675 ISRAEL HEPATITIS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 445
  • TABLE 676 ISRAEL HEPATITIS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 445
  • TABLE 677 ISRAEL HEPATITIS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 445
  • TABLE 678 ISRAEL PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 445
  • TABLE 679 ISRAEL VIRAL INFECTION IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 446
  • TABLE 680 ISRAEL RESPIRATORY TRACT INFECTION IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 446
  • TABLE 681 ISRAEL SEXUALLY TRANSMITTED INFECTION IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 447
  • TABLE 682 ISRAEL HOSPITAL ACQUIRED INFECTIONS IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 447
  • TABLE 683 ISRAEL OTHER INFECTIONS IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 448
  • TABLE 684 ISRAEL PCR BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 448
  • TABLE 685 ISRAEL PCR BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 448
  • TABLE 686 ISRAEL PCR BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 449
  • TABLE 687 ISRAEL PCR BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 449
  • TABLE 688 ISRAEL PCR BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 449
  • TABLE 689 REST OF MIDDLE EAST AND AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 450
  • TABLE 690 REST OF MIDDLE EAST AND AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 451
  • TABLE 691 REST OF MIDDLE EAST AND AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 452

LIST OF FIGURES

  • FIGURE 1 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET: SEGMENTATION 50
  • FIGURE 2 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET: DATA TRIANGULATION 53
  • FIGURE 3 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET: DROC ANALYSIS 54
  • FIGURE 4 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS 55
  • FIGURE 5 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET: COMPANY RESEARCH ANALYSIS 55
  • FIGURE 6 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET: INTERVIEW DEMOGRAPHICS 56
  • FIGURE 7 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET: MARKET APPLICATION COVERAGE GRID 58
  • FIGURE 8 GLOBAL PCR BASED INFECTIOUS DISEASE MARKET: DBMR MARKET POSITION GRID 60
  • FIGURE 9 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET: VENDOR SHARE ANALYSIS 61
  • FIGURE 10 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET: SEGMENTATION 65
  • FIGURE 11 THE GOVERNMENT INITIATIVES AND CAMPAIGNS TO PROMOTE DISEASE DIAGNOSIS IS DRIVING THE GROWTH OF THE GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET FROM 2024 TO 2031 66
  • FIGURE 12 THE INFECTION TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET IN 2024 AND 2031 66
  • FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET, AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2024 TO 2031 67
  • FIGURE 14 ASIA-PACIFIC IS THE FASTEST-GROWING MARKET FOR PCR-BASED INFECTIOUS DISEASE MARKET MANUFACTURERS IN THE FORECAST PERIOD OF 2024 TO 2031 68
  • FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE GLOBAL PCR-BASED INFECTIOUS DISEASES MARKET 72
  • FIGURE 16 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET : BY TEST TYPE, 2023 82
  • FIGURE 17 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET : BY TEST TYPE, 2024-2031 (USD THOUSAND) 83
  • FIGURE 18 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET : BY TEST TYPE, CAGR (2024-2031) 83
  • FIGURE 19 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET : BY TEST TYPE, LIFELINE CURVE 84
  • FIGURE 20 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET: BY INFECTION, 2023 100
  • FIGURE 21 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET: BY INFECTION, 2024-2031 (USD THOUSAND) 101
  • FIGURE 22 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET: BY INFECTION, CAGR (2024-2031) 101
  • FIGURE 23 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET: BY INFECTION, LIFELINE CURVE 102
  • FIGURE 24 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET: BY PATHOGEN, 2023 111
  • FIGURE 25 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET: BY PATHOGEN, 2024-2031 (USD THOUSAND) 112
  • FIGURE 26 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET: BY PATHOGEN, CAGR (2024-2031) 112
  • FIGURE 27 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET: BY PATHOGEN, LIFELINE CURVE 113
  • FIGURE 28 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET: BY PCR TECHNOLOGY, 2023 118
  • FIGURE 29 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET: BY PCR TECHNOLOGY, 2024-2031 (USD THOUSAND) 119
  • FIGURE 30 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET: BY PCR TECHNOLOGY, CAGR (2024-2031) 119
  • FIGURE 31 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET: BY PCR TECHNOLOGY, LIFELINE CURVE 120
  • FIGURE 32 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET : BY PATIENT TYPE, 2023 124
  • FIGURE 33 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET : BY PATIENT TYPE, 2024-2031 (USD THOUSAND) 125
  • FIGURE 34 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET : BY PATIENT TYPE, CAGR (2024-2031) 125
  • FIGURE 35 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET : BY PATIENT TYPE, LIFELINE CURVE 126
  • FIGURE 36 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET : BY TESTING, 2023 130
  • FIGURE 37 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET : BY TESTING, 2024-2031 (USD THOUSAND) 131
  • FIGURE 38 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET : BY TESTING, CAGR (2024-2031) 131
  • FIGURE 39 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET : BY TESTING, LIFELINE CURVE 132
  • FIGURE 40 GLOBAL PCR-BASED INFECTIOUS DISEASES MARKET: BY END USER, 2023 135
  • FIGURE 41 GLOBAL PCR-BASED INFECTIOUS DISEASES MARKET: BY END USER, 2024-2031 (USD THOUSAND) 136
  • FIGURE 42 GLOBAL PCR-BASED INFECTIOUS DISEASES MARKET: BY END USER, CAGR (2024-2031) 136
  • FIGURE 43 GLOBAL PCR-BASED INFECTIOUS DISEASES MARKET: BY END USER, LIFELINE CURVE 137
  • FIGURE 44 GLOBAL PCR-BASED INFECTIOUS DISEASES MARKET: SNAPSHOT (2023) 144
  • FIGURE 45 GLOBAL PCR-BASED INFECTIOUS DISEASES MARKET: COMPANY SHARE 2023 (%) 453
目次

The global PCR-based infectious diseases market is expected to reach USD 7,720,895.13 thousand by 2031 from USD 4,737,570.00 thousand in 2023, growing with a CAGR of 6.6% in the forecast period of 2024 to 2031.

Market Segmentation

Global PCR-based Infectious Diseases Market, By Test Type (Tuberculosis PCR Test, Hepatitis PCR Test, Human Immunodeficiency Virus (HIV) PCR Test, Influenza PCR Test, Human Papillomavirus (HPV) PCR Test, Gonorrhea PCT Test, Salmonellosis PCR Test, Rotavirus PCR Test, Bordetella PCR Test, H. Pylori PCR Test, Norovirus PCR Test, SARS (COVID-19) PCR Test, Enterococcus PCR Test, Chlamydia Trachomatis Genital PCR Test, C. Difficile (Clostridium Difficile) PCR Test, Carbapenem-Resistant Enterobacteriaceae (CRE) PCR Test, Mycoplasma Genitalium (MG) PCR Test, Methicillin-Resistant Staphylococcus Aureus (MRSA) PCR Test, and Other PCR Test), Infection (Viral Infection, Respiratory Tract Infection, Sexually Transmitted Infection, Hospital Acquired Infections, and Other Infections), Pathogen (Viral, Bacterial, Fungal, Protozoa, and Others), PCR Technology (RT PCR, Multiplex PCR, and Others), Patient Type (Geriatric, Pediatric, and Adults), Testing (Laboratory Based Testing and Point of Care Testing), End User (Diagnostic Centers, Hospital, Academic and Research Institutes, Community Health Centers, Clinics, Home Healthcare, and Others), Country (U.S., Canada, Mexico, Germany, U.K., Italy, France, Spain, Russia, Switzerland, Turkey, Belgium, Netherlands, Hungary, Rest of Europe, Japan, China, South Korea, India, Singapore, Thailand, Indonesia, Malaysia, Philippines, Australia, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Egypt, Saudi Arabia, U.A.E., Israel, and Rest of Middle East and Africa) - Industry Trends and Forecast to 2031

Overview of Global PCR-based Infectious Diseases Market Dynamics

  • Driver
  • Increasing PCR-based research activities
  • Restraint
  • High cost of PCR test services
  • Opportunity
  • Disease surveillance for early detection and monitoring of infectious diseases

Market Players

Some of the major market players operating in the global PCR-based infectious diseases market are:

  • DNA Labs India
  • DrSafeHands
  • Ganesh Diagnostic & Imaging Centre Pvt. Ltd.
  • Max Lab
  • MicroGen Diagnostics
  • pathlab
  • The Washington Travel Clinic
  • Clarewell Clinics
  • AZOVA
  • One Life Home Health Care Center
  • LalpathLabs

TABLE OF CONTENTS

1 INTRODUCTION 45

  • 1.1 OBJECTIVES OF THE STUDY 45
  • 1.2 MARKET DEFINITION 45
  • 1.3 OVERVIEW OF GLOBAL PCR-BASED INFECTIOUS DISEASES MARKET 45
  • 1.4 CURRENCY AND PRICING 46
  • 1.5 LIMITATIONS 47
  • 1.6 MARKETS COVERED 47

2 MARKET SEGMENTATION 50

  • 2.1 MARKETS COVERED 50
  • 2.2 GEOGRAPHICAL SCOPE 51
  • 2.3 YEARS CONSIDERED FOR THE STUDY 52
  • 2.4 DBMR TRIPOD DATA VALIDATION MODEL 53
  • 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 56
  • 2.6 MULTIVARIATE MODELLING 57
  • 2.7 MARKET APPLICATION COVERAGE GRID 58
  • 2.8 TEST TYPE LIFELINE CURVE 59
  • 2.9 DBMR MARKET POSITION GRID 60
  • 2.10 VENDOR SHARE ANALYSIS 61
  • 2.11 SECONDARY SOURCES 62
  • 2.12 ASSUMPTIONS 62

3 EXECUTIVE SUMMARY 63

4 PREMIUM INSIGHTS 66

  • 4.1 PESTEL ANALYSIS 69
  • 4.2 PORTER'S FIVE FORCES 70

5 MARKET OVERVIEW 71

  • 5.1 DRIVERS 73
    • 5.1.1 INCREASING PCR-BASED RESEARCH ACTIVITIES 73
    • 5.1.2 RISING CASES OF INFECTIOUS DISEASES 73
    • 5.1.3 GOVERNMENT INITIATIVES AND CAMPAIGNS TO PROMOTE DISEASE DIAGNOSIS 74
  • 5.2 RESTRAINTS 75
    • 5.2.1 HIGH COST OF PCR TEST SERVICES 75
    • 5.2.2 SHORTAGE OF SKILLED LABORATORY TECHNICIANS 76
  • 5.3 OPPORTUNITIES 77
    • 5.3.1 DISEASE SURVEILLANCE FOR EARLY DETECTION AND MONITORING OF INFECTIOUS DISEASES 77
    • 5.3.2 RISING INNOVATIONS IN PCR TECHNOLOGY 77
    • 5.3.3 PERSONALIZED PCR-BASED STRATEGIES FOR TARGETED AND EFFECTIVE INTERVENTIONS 78
  • 5.4 CHALLENGES 79
    • 5.4.1 DATA SECURITY AND PRIVACY CONCERNS 79
    • 5.4.2 COMPLEXITY AND TECHNICAL EXPERTISE 79

6 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE 81

  • 6.1 OVERVIEW 82
  • 6.2 TUBERCULOSIS PCR TEST 88
  • 6.3 HEPATITIS PCR TEST 88
    • 6.3.1 HEPATITIS C PCR TEST 89
    • 6.3.2 HEPATITIS B PCR TEST 89
  • 6.4 HUMAN IMMUNODEFICIENCY VIRUS (HIV) PCR TEST 90
  • 6.5 INFLUENZA PCR TEST 90
  • 6.6 HUMAN PAPILLOMAVIRUS (HPV) PCR TEST 91
  • 6.7 CHLAMYDIA TRACHOMATIS GENITAL PCR TEST 91
  • 6.8 GONORRHEA PCR TEST 92
  • 6.9 SALMONELLOSIS PCR TEST 92
  • 6.10 ROTAVIRUS PCR TEST 93
  • 6.11 BORDETELLA PCR TEST 93
  • 6.12 H. PYLORI PCR TEST 94
  • 6.13 SARS (COVID-19) PCR TEST 94
  • 6.14 NOROVIRUS PCR TEST 95
  • 6.15 C.DIFFICILE (CLOSTRIDIUM DIFFICILE) PCR TEST 95
  • 6.16 CARBAPENEM-RESISTANT ENTEROBACTERIACEAE (CRE) PCR TEST 96
  • 6.17 ENTEROCOCCUS PCR TEST 96
  • 6.18 MYCOPLASMA GENITALIUM (MG) PCR TEST 97
  • 6.19 METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) PCR TEST 97
  • 6.20 OTHERS PCR TEST 98

7 GLOBAL PCR-BASED INFECTIOUS DIISEASES MARKET, BY INFECTION 99

  • 7.1 OVERVIEW 100
  • 7.2 VIRAL INFECTION 103
    • 7.2.1 SARS (COVID-19) INFECTION 103
    • 7.2.2 ROTAVIRUS INFECTION 103
    • 7.2.3 NOROVIRUS INFECTION 103
    • 7.2.4 OTHERS 104
  • 7.3 RESPIRATORY TRACT INFECTION 104
    • 7.3.1 INFLUENZA 104
    • 7.3.2 TUBERCULOSIS 104
    • 7.3.3 BORDETELLA 105
  • 7.4 SEXUALLY TRANSMITTED INFECTION 105
    • 7.4.1 CHLAMYDIA TRACHOMATIS GENITAL INFECTION 106
    • 7.4.2 GONORRHEA 106
    • 7.4.3 HEAPTITIS 106
    • 7.4.4 HUMAN IMMUNODEFICIENCY VIRUS (HIV) 106
    • 7.4.5 HUMAN PAPILLOMAVIRUS (HPV) 106
    • 7.4.6 MYCOPLASMA GENITALIUM (MG) 106
    • 7.4.7 OTHERS 106
  • 7.5 HOSPITAL ACQUIRED INFECTIONS 107
    • 7.5.1 C.DIFFICILE (CLOSTRIDIUM DIFFICILE) 107
    • 7.5.2 CARBAPENEM- RESISTANT ENTEROBACTERIACEAE (CRE) 107
    • 7.5.3 METHICILIN- RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) 108
    • 7.5.4 OTHERS 108
  • 7.6 OTHER INFECTIONS 108
    • 7.6.1 SALMONELLOSIS 108
    • 7.6.2 H. PYLORI 109
    • 7.6.3 ENTEROCOCCUS INFECTIONS 109
    • 7.6.4 OTHERS 109

8 GLOBAL PCR-BASED INFECTIOUS DIISEASES MARKET, BY PATHOGEN 110

  • 8.1 OVERVIEW 111
  • 8.2 VIRAL 114
  • 8.3 BACTERIAL 114
  • 8.4 FUNGAL 115
  • 8.5 PROTOZOA 115
  • 8.6 OTHERS 116

9 GLOBAL PCR-BASED INFECTIOUS DIISEASES MARKET, BY PCR TECHNOLOGY 117

  • 9.1 OVERVIEW 118
  • 9.2 RT PCR 121
  • 9.3 MULTIPLEX PCR 121
  • 9.4 OTHERS 122

10 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE 123

  • 10.1 OVERVIEW 124
  • 10.2 GERIATRIC 127
  • 10.3 PEDIATRIC 127
  • 10.4 ADULTS 128

11 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING 129

  • 11.1 OVERVIEW 130
  • 11.2 LABORATORY BASED TESTING 133
  • 11.3 POINT OF CARE TESTING 133

12 GLOBAL PCR-BASED INFECTIOUS DISEASES MARKET, BY END USER 134

  • 12.1 OVERVIEW 135
  • 12.2 DIAGNOSTIC CENTERS 138
  • 12.3 HOSPITAL 138
  • 12.4 CLINICS 139
  • 12.5 COMMUNITY HEALTH CENTERS 139
  • 12.6 ACADEMIC AND RESEARCH INSTITUTES 140
  • 12.7 HOME HEALTHCARE 140
  • 12.8 OTHERS 141

13 GLOBAL PCR-BASED INFECTIOUS DISEASES MARKET, BY REGION 142

  • 13.1 OVERVIEW 143
  • 13.2 NORTH AMERICA 147
    • 13.2.1 U.S. 156
    • 13.2.2 CANADA 164
    • 13.2.3 MEXICO 172
  • 13.3 EUROPE 180
    • 13.3.1 GERMANY 189
    • 13.3.2 FRANCE 197
    • 13.3.3 U.K. 205
    • 13.3.4 ITALY 213
    • 13.3.5 RUSSIA 221
    • 13.3.6 SPAIN 229
    • 13.3.7 TURKEY 237
    • 13.3.8 NETHERLANDS 245
    • 13.3.9 SWITZERLAND 253
    • 13.3.10 BELGIUM 261
    • 13.3.11 HUNGARY 269
    • 13.3.12 REST OF EUROPE 277
  • 13.4 ASIA PACIFIC 280
    • 13.4.1 CHINA 290
    • 13.4.2 AUSTRALIA 298
    • 13.4.3 JAPAN 306
    • 13.4.4 INDIA 314
    • 13.4.5 SOUTH KOREA 322
    • 13.4.6 SINGAPORE 330
    • 13.4.7 MALAYISA 338
    • 13.4.8 THAILAND 346
    • 13.4.9 INDONESIA 354
    • 13.4.10 PHILIPPINES 362
    • 13.4.11 REST OF ASIA-PACIFIC 370
  • 13.5 SOUTH AMERICA 373
    • 13.5.1 BRAZIL 382
    • 13.5.2 ARGENTINA 390
    • 13.5.3 REST OF SOUTH AMERICA 398
  • 13.6 MIDDLE EAST AND AFRICA 401
    • 13.6.1 SOUTH AFRICA 410
    • 13.6.2 U.A.E. 418
    • 13.6.3 SAUDI ARABIA 426
    • 13.6.4 EGYPT 434
    • 13.6.5 ISRAEL 442
    • 13.6.6 REST OF MIDDLE EAST AND AFRICA 450

14 GLOBAL PCR-BASED INFECTIOUS DISEASES MARKET: COMPANY LANDSCAPE 453

  • 14.1 COMPANY SHARE ANALYSIS: GLOBAL 453

15 SWOT ANALYSIS 454

16 COMPANY PROFILE 455

  • 16.1 MICROGEN DIAGNOSTICS 455
    • 16.1.1 COMPANY SNAPSHOT 455
    • 16.1.2 SERVICE PORTFOLIO 455
    • 16.1.3 RECENT DEVELOPMENTS 456
  • 16.2 MAX LAB 457
    • 16.2.1 COMPANY SNAPSHOT 457
    • 16.2.2 SERVICE PORTFOLIO 457
  • 16.3 DNA LABS INDIA 459
    • 16.3.1 COMPANY SNAPSHOT 459
    • 16.3.2 SERVICE PORTFOLIO 459
    • 16.3.3 RECENT DEVELOPMENT 460
  • 16.4 GANESH DIAGNOSTIC & IMAGING CENTRE PVT. LTD. 461
    • 16.4.1 COMPANY SNAPSHOT 461
    • 16.4.2 SERVICE PORTFOLIO 461
    • 16.4.3 RECENT DEVELOPMENT 462
  • 16.5 LALPATHLABS 463
    • 16.5.1 COMPANY SNAPSHOT 463
    • 16.5.2 REVENUE ANALYSIS 463
    • 16.5.3 PRODUCT PORTFOLIO 464
    • 16.5.4 RECENT DEVELOPMENTS 464
  • 16.6 AZOVA 465
    • 16.6.1 COMPANY SNAPSHOT 465
    • 16.6.2 PRODUCT PORTFOLIO 465
    • 16.6.3 RECENT DEVELOPMENTS 465
  • 16.7 CLAREWELL CLINICS 466
    • 16.7.1 COMPANY SNAPSHOT 466
    • 16.7.2 PRODUCT DESCRIPTION 466
    • 16.7.3 RECENT DEVELOPMENTS 466
  • 16.8 DRSAFEHANDS 467
    • 16.8.1 COMPANY SNAPSHOT 467
    • 16.8.2 SERVICE PORTFOLIO 467
    • 16.8.3 RECENT DEVELOPMENT 467
  • 16.9 ONE LIFE HOME HEALTH CARE CENTER 468
    • 16.9.1 COMPANY SNAPSHOT 468
    • 16.9.2 PRODUCT DESCRIPTION 468
    • 16.9.3 RECENT DEVELOPMENTS 468
  • 16.10 PATHLAB 469
    • 16.10.1 COMPANY SNAPSHOT 469
    • 16.10.2 SERVICE PORTFOLIO 469
    • 16.10.3 RECENT DEVELOPMENT 469
  • 16.11 THE WASHINGTON TRAVEL CLINIC 470
    • 16.11.1 COMPANY SNAPSHOT 470
    • 16.11.2 SERVICE PORTFOLIO 470
    • 16.11.3 RECENT DEVELOPMENT 471

17 QUESTIONNAIRE 472

18 RELATED REPORTS 476